CDKN3 and breast carcinoma: Various studies have indicated that butyrate limits the proliferation of breast cancer cell lines by functioning as an histone deacetylase inhibitors and stimulating the formation of cyclin-dependent kinase inhibitor p21 [[77], [78], [79]].